New role of PTGES3 uncovered in liver cancer growth and immune evasion

A research team led by Prof. Wang Hongzhi at the Hefei Institutes of Physical Science, Chinese Academy of Sciences, has found a novel role of prostaglandin E synthase 3 (PTGES3) in liver cancer, revealing how it drives both tumor growth and immune suppression.

The study was published in Molecular Biomedicine.

Hepatocellular carcinoma (HCC) is a highly lethal liver cancer with limited treatment outcomes. Understanding the key regulators of tumor progression and immune suppression is important for improving therapy.

In this study, PTGES3, a cytoplasmic co-chaperone of HSP90, was identified as a nuclear transcriptional regulator. It was significantly overexpressed in HCC and was associated with poor patient outcomes.

PTGES3 promoted the growth and spread of HCC cells through the PI3K/AKT/mTOR pathway. In a diethylnitrosamine (DEN)-induced mouse model, reducing Ptges3 in liver cells significantly suppressed tumor growth. Single-cell RNA sequencing further showed that lower Ptges3 levels reshaped the tumor immune environment, with fewer M2 macrophages.

PTGES3 activated SP1 by binding to its promoter, leading to increased TGF-β production. This promoted tumor growth and enhanced immune suppression. Blocking TGF-β signaling reversed these effects, suggesting that PTGES3 acts independently of its classical chaperon role.

The findings identify the PTGES3/SP1/TGF-β axis as a potential therapeutic target, offering new strategies for combining targeted therapy with immunotherapy in liver cancer.

Who’s behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries.

Full profile →

Advertisements

Andrew Zinin

Master’s in physics with research experience. Long-time science news enthusiast. Plays key role in Science X’s editorial success.

Full profile →